Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: An open, uncontrolled pilot study

Gianantonio Saviola, Lul Abdi Ali, Paola Rossini, Lorella Campostrini, Alessandro Coppini, Mario Gori, Angela Ianaro, Mariarosaria Bucci, Gilberto de Nucci, Giuseppe Cirino

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective. In 1996 we found by serendipity that 2 patients with rheumatoid arthritis (RA) who were taking clarithromycin (CM) to eradicate Helicobacter pylori experienced a regression of their RA symptoms. Following this observation, we tested the hypothesis that this reduction in symptoms could have been caused by CM administration. Methods. We performed a 6-month, open, uncontrolled pilot study on 18 patients (14 females and 4 males, mean age 62 yrs.) with RA who had previously received DMARDs (mean 2.6) and discontinued the treatment at least one month earlier because lack of efficacy or severe side effects. Patients were treated with CM at the dose of 500 mg twice per day for the first 10 days, followed by a daily maintenance dose of 250 mg twice per day. Results. 4/18 patients did not complete the treatment, 2/18 were not responsive to the treatment and 2/18 discontinued the treatment. Following ACR criteria the improvement was: 10 patients ACR 20; 6 patients ACR 50; and 2 patients ACR 70. The remaining 4 patients did not reach ACR 20 since either the number of tender or swollen joints was not to the level required. Reductions in PGE2 and soluble phospholipase A2 plasma levels were closely related to CM plasma levels. Conclusions. Our findings suggest that CM treatment can be beneficial in those patients who are not responsive to or cannot tolerate DMARDs. No definitive conclusions can be drawn based on the present study, due to the small sample size involved.

Original languageEnglish
Pages (from-to)373-378
Number of pages6
JournalClinical and Experimental Rheumatology
Volume20
Issue number3
Publication statusPublished - May 2002

Fingerprint

Antirheumatic Agents
Clarithromycin
Rheumatoid Arthritis
Therapeutics
Phospholipases A2
Dinoprostone
Helicobacter pylori
Sample Size
Joints

Keywords

  • Antibiotics
  • Clarithromycin
  • Macrolide
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs : An open, uncontrolled pilot study. / Saviola, Gianantonio; Abdi Ali, Lul; Rossini, Paola; Campostrini, Lorella; Coppini, Alessandro; Gori, Mario; Ianaro, Angela; Bucci, Mariarosaria; de Nucci, Gilberto; Cirino, Giuseppe.

In: Clinical and Experimental Rheumatology, Vol. 20, No. 3, 05.2002, p. 373-378.

Research output: Contribution to journalArticle

Saviola, G, Abdi Ali, L, Rossini, P, Campostrini, L, Coppini, A, Gori, M, Ianaro, A, Bucci, M, de Nucci, G & Cirino, G 2002, 'Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: An open, uncontrolled pilot study', Clinical and Experimental Rheumatology, vol. 20, no. 3, pp. 373-378.
Saviola, Gianantonio ; Abdi Ali, Lul ; Rossini, Paola ; Campostrini, Lorella ; Coppini, Alessandro ; Gori, Mario ; Ianaro, Angela ; Bucci, Mariarosaria ; de Nucci, Gilberto ; Cirino, Giuseppe. / Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs : An open, uncontrolled pilot study. In: Clinical and Experimental Rheumatology. 2002 ; Vol. 20, No. 3. pp. 373-378.
@article{3c52b841373446ed802d8e05d2035623,
title = "Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs: An open, uncontrolled pilot study",
abstract = "Objective. In 1996 we found by serendipity that 2 patients with rheumatoid arthritis (RA) who were taking clarithromycin (CM) to eradicate Helicobacter pylori experienced a regression of their RA symptoms. Following this observation, we tested the hypothesis that this reduction in symptoms could have been caused by CM administration. Methods. We performed a 6-month, open, uncontrolled pilot study on 18 patients (14 females and 4 males, mean age 62 yrs.) with RA who had previously received DMARDs (mean 2.6) and discontinued the treatment at least one month earlier because lack of efficacy or severe side effects. Patients were treated with CM at the dose of 500 mg twice per day for the first 10 days, followed by a daily maintenance dose of 250 mg twice per day. Results. 4/18 patients did not complete the treatment, 2/18 were not responsive to the treatment and 2/18 discontinued the treatment. Following ACR criteria the improvement was: 10 patients ACR 20; 6 patients ACR 50; and 2 patients ACR 70. The remaining 4 patients did not reach ACR 20 since either the number of tender or swollen joints was not to the level required. Reductions in PGE2 and soluble phospholipase A2 plasma levels were closely related to CM plasma levels. Conclusions. Our findings suggest that CM treatment can be beneficial in those patients who are not responsive to or cannot tolerate DMARDs. No definitive conclusions can be drawn based on the present study, due to the small sample size involved.",
keywords = "Antibiotics, Clarithromycin, Macrolide, Rheumatoid arthritis",
author = "Gianantonio Saviola and {Abdi Ali}, Lul and Paola Rossini and Lorella Campostrini and Alessandro Coppini and Mario Gori and Angela Ianaro and Mariarosaria Bucci and {de Nucci}, Gilberto and Giuseppe Cirino",
year = "2002",
month = "5",
language = "English",
volume = "20",
pages = "373--378",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",

}

TY - JOUR

T1 - Clarithromycin in rheumatoid arthritis patients not responsive to disease-modifying antirheumatic drugs

T2 - An open, uncontrolled pilot study

AU - Saviola, Gianantonio

AU - Abdi Ali, Lul

AU - Rossini, Paola

AU - Campostrini, Lorella

AU - Coppini, Alessandro

AU - Gori, Mario

AU - Ianaro, Angela

AU - Bucci, Mariarosaria

AU - de Nucci, Gilberto

AU - Cirino, Giuseppe

PY - 2002/5

Y1 - 2002/5

N2 - Objective. In 1996 we found by serendipity that 2 patients with rheumatoid arthritis (RA) who were taking clarithromycin (CM) to eradicate Helicobacter pylori experienced a regression of their RA symptoms. Following this observation, we tested the hypothesis that this reduction in symptoms could have been caused by CM administration. Methods. We performed a 6-month, open, uncontrolled pilot study on 18 patients (14 females and 4 males, mean age 62 yrs.) with RA who had previously received DMARDs (mean 2.6) and discontinued the treatment at least one month earlier because lack of efficacy or severe side effects. Patients were treated with CM at the dose of 500 mg twice per day for the first 10 days, followed by a daily maintenance dose of 250 mg twice per day. Results. 4/18 patients did not complete the treatment, 2/18 were not responsive to the treatment and 2/18 discontinued the treatment. Following ACR criteria the improvement was: 10 patients ACR 20; 6 patients ACR 50; and 2 patients ACR 70. The remaining 4 patients did not reach ACR 20 since either the number of tender or swollen joints was not to the level required. Reductions in PGE2 and soluble phospholipase A2 plasma levels were closely related to CM plasma levels. Conclusions. Our findings suggest that CM treatment can be beneficial in those patients who are not responsive to or cannot tolerate DMARDs. No definitive conclusions can be drawn based on the present study, due to the small sample size involved.

AB - Objective. In 1996 we found by serendipity that 2 patients with rheumatoid arthritis (RA) who were taking clarithromycin (CM) to eradicate Helicobacter pylori experienced a regression of their RA symptoms. Following this observation, we tested the hypothesis that this reduction in symptoms could have been caused by CM administration. Methods. We performed a 6-month, open, uncontrolled pilot study on 18 patients (14 females and 4 males, mean age 62 yrs.) with RA who had previously received DMARDs (mean 2.6) and discontinued the treatment at least one month earlier because lack of efficacy or severe side effects. Patients were treated with CM at the dose of 500 mg twice per day for the first 10 days, followed by a daily maintenance dose of 250 mg twice per day. Results. 4/18 patients did not complete the treatment, 2/18 were not responsive to the treatment and 2/18 discontinued the treatment. Following ACR criteria the improvement was: 10 patients ACR 20; 6 patients ACR 50; and 2 patients ACR 70. The remaining 4 patients did not reach ACR 20 since either the number of tender or swollen joints was not to the level required. Reductions in PGE2 and soluble phospholipase A2 plasma levels were closely related to CM plasma levels. Conclusions. Our findings suggest that CM treatment can be beneficial in those patients who are not responsive to or cannot tolerate DMARDs. No definitive conclusions can be drawn based on the present study, due to the small sample size involved.

KW - Antibiotics

KW - Clarithromycin

KW - Macrolide

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0036558941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036558941&partnerID=8YFLogxK

M3 - Article

C2 - 12102474

AN - SCOPUS:0036558941

VL - 20

SP - 373

EP - 378

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 3

ER -